drugset / Trial / NCT07791758
A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
Phase 1/2
Not yet recruiting
369 enrolled
Nanjing Leads Biolabs Co.,Ltd
Sun Yat-Sen University Cancer Center · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is an open-label, multi-center Phase Ib/II clinical trial evaluating the safety and efficacy of LBL-024 in combination with other drugs for the treatment of metastatic colorectal carcinoma (mCRC), aiming to evaluate the safety and efficacy of LBL-024 in combination with other drugs in the treatment of mCRC patients.
Timeline
- Start
- 2026-09-04
- Primary completion
- 2030-09-04
- Completion
- 2030-09-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Capecitabine | Small molecule | — | Oral |
| Subject | Fruquintinib | Small molecule | — | Oral |
| Subject | LBL-024 | Unknown | — | Intravenous |
| Subject | Oxaliplatin | Small molecule | — | Intravenous |